This conference discussed the latest important findings from Florey and around the world on the cause of Alzheimer's disease and the search for its cure. The talk covered the underlying biology progression of Alzheimer's disease, current and future diagnostic tools and therapeutic trials in order to delay or reverse the disease.
Professor Paul Maruff is chair of the clinical panel of the Australian Imaging Biomarkers and Lifestyle (AIBL) study and is also on the AIBL executive committee. He is also scientific director of CogState Ltd that specializes in the development of techniques to evaluate, analyze and report on cognitive and behavioral outcomes in neuropsychiatric and neurodegenerative diseases.
Prof. Maruff and his team of psychologists and statisticians have been at the forefront of understanding the early or clinical development of Alzheimer's disease and how this is influenced by biological and genetic factors as well as lifestyle variables and the state of cheer up.
His research team has shown that cognitive impairment is a crucial marker of neurodegenerative disease. They have associated cognitive impairment objectively classified with biomarkers of Alzheimer's disease. These findings have put the Alzheimer's group in Melbourne at the forefront of understanding the disease, and group technologies and approaches to early identification of AD have been included in multiple international studies and studies of Alzheimer's.
Prof Maruff is a member of advisory boards to many large pharmaceutical companies and biotechnology companies that are conducting clinical trials with drugs designed to delay or even cure Alzheimer's disease, including the A4 study and DIAN-TU studies at Florey.
Video credits to The Florey Institute of Neuroscience and Mental Health YouTube channel